Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation
Silybin, a peculiar flavonoid compound derived from the fruit and seeds of Silybum marianum, exhibits strong anti-inflammatory activities. In the present study, we found that silybin effectively alleviated experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), v...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.659678/full |
| _version_ | 1831559822699397120 |
|---|---|
| author | Huan-Li Yang Xiao-Wu Shi |
| author_facet | Huan-Li Yang Xiao-Wu Shi |
| author_sort | Huan-Li Yang |
| collection | DOAJ |
| description | Silybin, a peculiar flavonoid compound derived from the fruit and seeds of Silybum marianum, exhibits strong anti-inflammatory activities. In the present study, we found that silybin effectively alleviated experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), via inhibition of dendritic cell (DC) activation and Th17 cell differentiation. Silybin treatment greatly ameliorated the disease severity and significantly declined inflammation and demyelination of the central nervous system (CNS) of EAE mice. Consistent with the disease development, silybin-treated bone marrow-derived DCs (BM-DCs) exhibited reduced costimulatory molecules (e.g., CD80 and CD86) and MHC II expression. These results demonstrated the distinguished bioactivity of silybin for suppressing DC activation, inhibiting pathogenic Th17 inflammatory cell responses, and, eventually, alleviating EAE severity. Taken together, our results show that silybin has high potential for the development of a novel therapeutic agent for the treatment of autoimmune diseases such as MS. |
| first_indexed | 2024-12-17T05:34:58Z |
| format | Article |
| id | doaj.art-cf7e6e9d71df4fbbb7cdf31cd5545655 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-17T05:34:58Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-cf7e6e9d71df4fbbb7cdf31cd55456552022-12-21T22:01:38ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-09-011210.3389/fneur.2021.659678659678Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell DifferentiationHuan-Li Yang0Xiao-Wu Shi1Xian Yang Central Hospital, Xianyang, ChinaXian Yang Central Blood Station, Xianyang, ChinaSilybin, a peculiar flavonoid compound derived from the fruit and seeds of Silybum marianum, exhibits strong anti-inflammatory activities. In the present study, we found that silybin effectively alleviated experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), via inhibition of dendritic cell (DC) activation and Th17 cell differentiation. Silybin treatment greatly ameliorated the disease severity and significantly declined inflammation and demyelination of the central nervous system (CNS) of EAE mice. Consistent with the disease development, silybin-treated bone marrow-derived DCs (BM-DCs) exhibited reduced costimulatory molecules (e.g., CD80 and CD86) and MHC II expression. These results demonstrated the distinguished bioactivity of silybin for suppressing DC activation, inhibiting pathogenic Th17 inflammatory cell responses, and, eventually, alleviating EAE severity. Taken together, our results show that silybin has high potential for the development of a novel therapeutic agent for the treatment of autoimmune diseases such as MS.https://www.frontiersin.org/articles/10.3389/fneur.2021.659678/fullEAEmultiple sclerosissilybindendritic cellT cell |
| spellingShingle | Huan-Li Yang Xiao-Wu Shi Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation Frontiers in Neurology EAE multiple sclerosis silybin dendritic cell T cell |
| title | Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation |
| title_full | Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation |
| title_fullStr | Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation |
| title_full_unstemmed | Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation |
| title_short | Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation |
| title_sort | silybin alleviates experimental autoimmune encephalomyelitis by suppressing dendritic cell activation and th17 cell differentiation |
| topic | EAE multiple sclerosis silybin dendritic cell T cell |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2021.659678/full |
| work_keys_str_mv | AT huanliyang silybinalleviatesexperimentalautoimmuneencephalomyelitisbysuppressingdendriticcellactivationandth17celldifferentiation AT xiaowushi silybinalleviatesexperimentalautoimmuneencephalomyelitisbysuppressingdendriticcellactivationandth17celldifferentiation |